Cargando…

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod

Fingolimod represents a highly effective disease-modifying drug in patients with active relapsing-remitting multiple sclerosis (RRMS). Its immunosuppressive effects can mediate adverse events like increased risk of cancer development or appearance of opportunistic infections. Progressive multifocal...

Descripción completa

Detalles Bibliográficos
Autores principales: Maass, Fabian, von Gottberg, Philipp, Franz, Jonas, Stadelmann, Christine, Bähr, Mathias, Weber, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886972/
https://www.ncbi.nlm.nih.gov/pubmed/33613428
http://dx.doi.org/10.3389/fneur.2021.561158
_version_ 1783651906098298880
author Maass, Fabian
von Gottberg, Philipp
Franz, Jonas
Stadelmann, Christine
Bähr, Mathias
Weber, Martin S.
author_facet Maass, Fabian
von Gottberg, Philipp
Franz, Jonas
Stadelmann, Christine
Bähr, Mathias
Weber, Martin S.
author_sort Maass, Fabian
collection PubMed
description Fingolimod represents a highly effective disease-modifying drug in patients with active relapsing-remitting multiple sclerosis (RRMS). Its immunosuppressive effects can mediate adverse events like increased risk of cancer development or appearance of opportunistic infections. Progressive multifocal leukoencephalopathy (PML)–representing a severe opportunistic infection–has been only infrequently described during Fingolimod treatment. Here, we present a case of a 63-year-old women with pre-diagnosed RRMS who presented with new multiple cerebral lesions in a routine MRI scan, also including a tumefactive lesion in the left parietal lobe, eventually leading to the diagnosis of brain metastases derived by an adenocarcinoma of the lung. Additionally, a JCV-DNA-PCR in the cerebrospinal fluid revealed positive results, corresponding to a paraclinical progressive multifocal leukoencephalopathy. In conclusion, adverse events potentially associated with immunosuppression can occur during Fingolimod treatment. In this context, the occurrence of cancer and opportunistic infections should be carefully monitored. Here, we report a case in which JCV-DNA-PCR in the cerebrospinal fluid suggests asymptomatic PML and simultaneously lung cancer brain metastases developed. While it is rather unlikely that either event occurred as an adverse event of fingolimod treatment, a contributing effect cannot be formally excluded.
format Online
Article
Text
id pubmed-7886972
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78869722021-02-18 Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod Maass, Fabian von Gottberg, Philipp Franz, Jonas Stadelmann, Christine Bähr, Mathias Weber, Martin S. Front Neurol Neurology Fingolimod represents a highly effective disease-modifying drug in patients with active relapsing-remitting multiple sclerosis (RRMS). Its immunosuppressive effects can mediate adverse events like increased risk of cancer development or appearance of opportunistic infections. Progressive multifocal leukoencephalopathy (PML)–representing a severe opportunistic infection–has been only infrequently described during Fingolimod treatment. Here, we present a case of a 63-year-old women with pre-diagnosed RRMS who presented with new multiple cerebral lesions in a routine MRI scan, also including a tumefactive lesion in the left parietal lobe, eventually leading to the diagnosis of brain metastases derived by an adenocarcinoma of the lung. Additionally, a JCV-DNA-PCR in the cerebrospinal fluid revealed positive results, corresponding to a paraclinical progressive multifocal leukoencephalopathy. In conclusion, adverse events potentially associated with immunosuppression can occur during Fingolimod treatment. In this context, the occurrence of cancer and opportunistic infections should be carefully monitored. Here, we report a case in which JCV-DNA-PCR in the cerebrospinal fluid suggests asymptomatic PML and simultaneously lung cancer brain metastases developed. While it is rather unlikely that either event occurred as an adverse event of fingolimod treatment, a contributing effect cannot be formally excluded. Frontiers Media S.A. 2021-02-03 /pmc/articles/PMC7886972/ /pubmed/33613428 http://dx.doi.org/10.3389/fneur.2021.561158 Text en Copyright © 2021 Maass, von Gottberg, Franz, Stadelmann, Bähr and Weber. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Maass, Fabian
von Gottberg, Philipp
Franz, Jonas
Stadelmann, Christine
Bähr, Mathias
Weber, Martin S.
Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
title Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
title_full Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
title_fullStr Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
title_full_unstemmed Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
title_short Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
title_sort case report: findings suggestive of paraclinical progressive multifocal leukoencephalopathy and lung cancer-derived brain metastases in an ms patient treated with fingolimod
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886972/
https://www.ncbi.nlm.nih.gov/pubmed/33613428
http://dx.doi.org/10.3389/fneur.2021.561158
work_keys_str_mv AT maassfabian casereportfindingssuggestiveofparaclinicalprogressivemultifocalleukoencephalopathyandlungcancerderivedbrainmetastasesinanmspatienttreatedwithfingolimod
AT vongottbergphilipp casereportfindingssuggestiveofparaclinicalprogressivemultifocalleukoencephalopathyandlungcancerderivedbrainmetastasesinanmspatienttreatedwithfingolimod
AT franzjonas casereportfindingssuggestiveofparaclinicalprogressivemultifocalleukoencephalopathyandlungcancerderivedbrainmetastasesinanmspatienttreatedwithfingolimod
AT stadelmannchristine casereportfindingssuggestiveofparaclinicalprogressivemultifocalleukoencephalopathyandlungcancerderivedbrainmetastasesinanmspatienttreatedwithfingolimod
AT bahrmathias casereportfindingssuggestiveofparaclinicalprogressivemultifocalleukoencephalopathyandlungcancerderivedbrainmetastasesinanmspatienttreatedwithfingolimod
AT webermartins casereportfindingssuggestiveofparaclinicalprogressivemultifocalleukoencephalopathyandlungcancerderivedbrainmetastasesinanmspatienttreatedwithfingolimod